The use of eicosapentaenoic acid in the treatment of chronic fatigue syndrome

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 4, 2004, Pages 399-401

  Puri, B K ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; DOCOSAHEXAENOIC ACID; ESSENTIAL FATTY ACID; GAMMA LINOLENIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; OMEGA 3 FATTY ACID;

CHRONIC FATIGUE SYNDROME; CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; FAT INTAKE; FOOD COMPOSITION; HUMAN; LIPID COMPOSITION; NEUROIMAGING; NEUROSPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SPECTROSCOPY; SYMPTOMATOLOGY;

EID: 1842453648     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.12.015     Document Type: Conference Paper

References (11)

1. K. Fukuda, S.E. Straus, I. Hickie, M.C. Sharpe, J.G. Dobbins, A. Komaroff, The chronic fatigue syndrome: a comprehensive approach to its definition and study, Ann. Intern. Med. 121 (1994) 953-959.
2. D.F. Horrobin, Essential fatty acids and the post-viral fatigue syndrome, in: R. Jenkins, J. Mowbray (Eds.), Post-viral Fatigue Syndrome, Wiley, Chichester, 1991, pp. 393-404.
3. J. Sands, D. Auperin, W. Snipes, Extreme sensitivity of enveloped viruses, including herpes simplex, to long-chain unsaturated monoglycerides and alcohols, Antimicrob. Agents Chemother. 15 (1979) 67-73.
4. B. Horowitz, M.P. Piet, A.M. Prince, C.A. Edwards, A. Lippin, L.A. Walakovits, Inactivation of lipid-enveloped viruses in labile blood derivatives by unsaturated fatty acids, Vox Sang 54 (1988) 14-20.
5. D.F. Horrobin, Phospholipid and fatty acid biochemistry in schizophrenia, in: M. Peet, I. Glen, D.F. Horrobin (Eds.), Phospholipid Spectrum Disorders in Psychiatry and Neurology, 2nd edition., Marius Press, Carnforth, Lancashire, 2003, pp. 123-162.
6. B.K. Puri, S.J. Counsell, R. Zaman, J. Main, A.G. Collins, J.V. Hajnal, N.J. Davey, Relative increase in choline in the occipital cortex in chronic fatigue syndrome, Acta Psychiatr. Scand. 106 (2002) 224-226.
7. J. Ruiz-Cabello, J.S. Cohen, Phospholipid metabolites as indicators of cancer cell function, NMR Biomed. 5 (1992) 226-233.
8. A. Chaudhuri, B.R. Condon, J.W. Gow, D. Brennan, D.M. Hadley, Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome, Neuroreport 14 (2003) 225-228.
9. B.K. Puri, J. Holmes, G. Hamilton. Eicosapentaenoic acid (EPA)-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. Int. J. Clin. Pract., in press.
10. P.O. Behan, W.M.H. Behan, D.F. Horrobin, A placebo-controlled trial of n-3, n-6, essential fatty acids in the treatment of postviral fatigue syndrome, Acta. Neurol. Scand. 82 (1990) 209-216.
11. G. Warren, M. McKendrick, M. Peet, The role of essential fatty acids in chronic fatigue syndrome: a case-controlled study of red-cell membrane essential fatty acids (EFA) and a placebo-controlled treatment study with high dose of EFA, Acta. Neurol. Scand. 99 (1999) 112-116.